Induced hypertension with norepinephrine

Phase 3Small molecule

Induced hypertension with norepinephrine is one of 53 small molecule programs targeting Cerebral Infarction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral InfarctionActive, not recruiting

HypertensionActive, not recruiting

Cerebral InfarctionPreclinical

Active, not recruiting

HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Induced hypertension with norepinephrine

UUMC Utrecht

Phase 3

1 2

Edarbi

Takeda

Preclinical

10 3

Benicar

Novartis

Preclinical

7 4

Apresoline

Novartis

Preclinical

7 5

Zebeta

Teva

Preclinical

6 6

Edarbi

Takeda

Preclinical

4 7

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 8

Alphagan

AbbVie

Preclinical

—9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 10

Avastin

BBio-Thera Solutions

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Recruiting

Cerebral Infarction

NCT07305922

Clinical

Trials by Indication[1]

Cerebral Infarction1 trial

Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension

Recruiting·RRegion Stockholm··NCT07305922·200 enrolled

Hypertension1 trial

Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study

Terminated·UUMC Utrecht·Phase 3·NCT00841633·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Induced hypertension with norepinephrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Induced hypertension with norepinephrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Induced hypertension with norepinephrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UMC Utrecht company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUMC Utrecht

Induced hypertension with norepinephrine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Cerebral Infarction1 trial

Hypertension1 trial

References

Drug Info

Quick Facts

Related News